Pacific Edge at risk of losing ‘significant’ revenue stream

Pacific Edge at risk of losing ‘significant’ revenue stream
The test has been used more than 10,000 times since it was first approved in 2020. (Image: Pacific Edge)
Dan Brunskill
Pacific Edge could have its cancer tests dropped by a major US health insurance company which is considering a new way to choose which tests are covered.  Medicare provider Novitas currently reimburses the use of Cxbladder but would not under a new process it has proposed. Currently, the health insurer reviews clinical evidence for each individual product but has proposed relying on third-party lists instead. Pacific Edge said if the proposal was adopted, Cxbladder would no longer receive reimbursement from Novitas, which makes up &ld...

More Markets

NZ sharemarket continues momentum, Skellerup sees green
Markets Market Close

NZ sharemarket continues momentum, Skellerup sees green

 The Red Band gumboot-maker said it earned $54.5m after tax. 

Tom Raynel 21 Aug 2025
Xero board faces 'first strike' over CEO pay
Markets

Xero board faces 'first strike' over CEO pay

Xero investors fire warning shot at directors willing to pay big for talent.

Staff reporters 21 Aug 2025
Auckland airport dynamics returning to normal
Markets

Auckland airport dynamics returning to normal

Yields are improving for airlines operating into Auckland, but earnings look flat ahead. 

Pattrick Smellie 21 Aug 2025